Welcome to our dedicated page for Royalty Pharma news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma stock.
Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $100 million in funding to Zealand Pharma in return for Zealand’s economic interests in rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera. Royalty Pharma will receive rights to a 1% royalty on potential future global net sales of rusfertide plus associated regulatory and commercial milestones.
The funding will be paid in two tranches: $50 million at closing and $50 million on the first anniversary of closing. Zealand will retain a 0.25% royalty on annual global net sales of rusfertide above $1.5 billion, while Royalty Pharma will retain a 0.75% royalty on sales above that threshold. The FDA has assigned a PDUFA goal date in Q3 2026 for rusfertide’s NDA in adults with polycythemia vera, and Takeda will be responsible for global commercialization.
Royalty Pharma (Nasdaq: RPRX) reported second quarter 2026 Royalty Receipts of $768 million, up 14% year over year, and Portfolio Receipts of $773 million, up 6%. Growth was led by Tremfya, Voranigo, Imdelltra and Evrysdi, partly offset by declines in Promacta and Imbruvica and sharply lower milestones and other contractual receipts.
Net cash provided by operating activities was $728 million and non-GAAP Adjusted EBITDA and Portfolio Cash Flow were each $736 million, both up from $633 million a year earlier. The company raised its 2026 Portfolio Receipts guidance to $3,400–$3,500 million, implying expected Royalty Receipts growth of 7–10%, and expects operating and professional costs to fall to 5.5–6.5% of Portfolio Receipts.
Royalty Pharma deployed $349 million of capital in the quarter and $877 million in the first half, announced up to $1.7 billion of 2026 transactions, repaid a $380 million term loan in July, paid $135 million in dividends and repurchased $45 million of shares. Cash and cash equivalents were $812 million and total debt $9.2 billion at June 30, 2026.
Royalty Pharma (Nasdaq: RPRX) appointed Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. He will lead outreach to academic and non-profit institutions and oversee the Royalty Pharma Translational Prize.
Raskin previously served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center, led healthcare and life sciences investing at AllianceBernstein’s venture fund, and held roles at Baker Brothers Investments and McKinsey. He holds an M.D. and a B.A. from Yale and lectures on drug development economics at Stanford and Yale.
Royalty Pharma (Nasdaq:RPRX) agreed to acquire a portion of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 ATTR-CM antibody cliramitug for up to $425 million, including $125 million upfront. Royalty Pharma will receive a 3%–4% royalty on worldwide net sales of cliramitug.
Royalty Pharma plans to pay Neurimmune an additional $125 million in the first quarter of 2027, with a further $175 million contingent on clinical and regulatory milestones. Cliramitug is in the Phase 3 DepleTTR-CM trial, with results expected in 2028 based on AstraZeneca guidance, targeting the >$7 billion ATTR-CM market, which grew over 40% in 2025.
Royalty Pharma (Nasdaq: RPRX) announced that its board of directors has approved a third quarter 2026 dividend of $0.235 per Class A ordinary share. The dividend is scheduled to be paid on September 10, 2026 to shareholders of record as of August 14, 2026.
According to Royalty Pharma, the company is the largest buyer of biopharmaceutical royalties and a major funder of industry innovation. Its portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates across leading biopharmaceutical companies.
Royalty Pharma (Nasdaq: RPRX) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before U.S. markets open. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with replay available on its website for at least 30 days.
Royalty Pharma (Nasdaq:RPRX) announced it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET. A live webcast and 30-day archive will be available on its investor events page.
Royalty Pharma (Nasdaq: RPRX) will present at two investor conferences in May 2026: BofA Securities Healthcare Conference on May 13, 2026 at 1:40 p.m. ET and RBC Capital Markets Global Healthcare Conference on May 19, 2026 at 10:00 a.m. ET.
Webcasts are available from the company’s Events page and will be archived for a minimum of 30 days.
Royalty Pharma (Nasdaq: RPRX) reported Q1 2026 results: Portfolio Receipts $925M (+10%), Royalty Receipts $887M (+13%), and net cash from operations $718M. The company announced up to $1.25B of new transactions and deployed $528M of capital. It raised full‑year 2026 Portfolio Receipts guidance to $3,325M–$3,450M and reported cash of $586M and debt principal of $9.2B.
Royalty Pharma (Nasdaq: RPRX) launched the Royalty Pharma Translational Prize, a new annual award to recognize translational medicine breakthroughs.
The Prize includes a $1 million award distributed among one or more established scientists; nominations open summer 2026 and the first laureate will be recognized in spring 2027 at the ABI conference.